Blue Jet Healthcare Ltd.
NSE: BLUEJETBlue Jet Healthcare Ltd.: A 30-second snapshot
Blue Jet Healthcare (BLUEJET) is a Pharma-sector contract manufacturer trading at ₹430.4, down 43.9% over 12 months and 58.1% below its 52-week high. The stock sits 21.4% below its 200-DMA of ₹547.5 while the RSI has returned to neutral at 47.5. Five-year revenue and earnings have contracted sharply (-39.6% and -59.4% respectively), with debt rising and a quality score of 27 out of 100 versus the Pharma peer median.
P/E
25.5
Forward P/E
24.2
ROE
—
Debt / Equity
1.64
Profit Margin
+27.9%
Div. Yield
+0.3%
5Y ROE > 15%
4/5
5Y FCF > 0
3/5
Quality
45/100
News
2 headlines · 1 positive · 1 negative
Urban Company, Blue Jet Healthcare shares: LKP analyst gives 'Buy' calls; check target prices, stop loss, more - Business Today
Business Today
Blue Jet Healthcare - FIIs slash stakes in 8 stocks over two quarters, shares crack up to 50%. Are you holding any? - The Economic Times
The Economic Times
Recent context
- ·An LKP analyst issued a constructive note on BLUEJET in early May 2026 (sourced via Business Today), citing a specific price target — this represents a named third-party view, not a VivaTrades assessment.
- ·Economic Times reported FII stake reductions in BLUEJET across two consecutive quarters, with the stock among those down up to 50% from recent peaks, as of April 2026.
- ·The 3-month price change of -2.66% alongside RSI at 47.5 and the stock trading above its 50-DMA (₹402.2) but below its 200-DMA (₹547.5) frames the current technical position as mid-range in its recovery range.
Strengths
- +Trailing profit margin of 27.88% is meaningfully high in absolute terms, suggesting the business retains pricing power on a per-unit basis even as revenue base has declined over 5 years.
- +PE of 25.5x (forward 24.2x) is the lowest in the 6-peer Pharma comparison set, where peers range from 26.5x (Dr Reddy) to 72.5x (Max Health) — the valuation gap is directly visible in the data.
- +FCF was positive in 3 of the available measurement years, and the consistency score of 72 out of 100 indicates earnings quality has not been uniformly poor over the full history.
- +ROE exceeded 15% in 4 of the measured years, indicating the business has operated at above-median capital efficiency in prior periods, though ROE data for the most recent year is unavailable.
Weaknesses
- −5-year earnings growth of -59.4% and revenue growth of -39.6% signal multi-year structural contraction beyond a single-quarter miss or cyclical trough.
- −Current price of ₹430.4 is 21.4% below the 200-DMA of ₹547.5; the stock has been below its 200-DMA for an extended period, consistent with a sustained downtrend in price.
- −Debt-to-equity of 1.643 with a rising debt trend, combined with a quality score of 27 out of 100 (ranked 4th of 6 peers), reflects balance sheet deterioration occurring alongside revenue decline.
- −FII ownership has been reduced across two consecutive quarters per recent news flow, indicating institutional selling pressure concurrent with the 43.9% 12-month price decline.
Open questions
- ?Is the 5-year revenue contraction of 39.6% attributable to a specific customer concentration, product cycle, or regulatory event, and has the underlying cause been resolved?
- ?Does the rising debt trend reflect investment in new capacity or working capital strain — and what does the trajectory of interest coverage look like over the past three years?
- ?At a PE of 25.5x against a backdrop of multi-year earnings decline, what earnings recovery rate is embedded in the current price, and how does that compare to analyst estimates?
- ?The profit margin of 27.88% has held despite falling revenues — is this margin sustainable if revenue stabilises at current levels, or is it partly supported by one-off factors?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| BLUEJET | Blue Jet Healthcare Ltd.You're viewing | 25.5 | — | 27 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.5 | +11.8% | 17 |
Technical state
Current price
₹430.40
SMA 50
₹402.20
SMA 200
₹547.46
RSI (14)
47.5 (neutral)
From 52w high
-58.0%
1Y return
-43.9%
3M return
-2.7%
50-DMA
Above
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- high5-year earnings growth of -59.4% and revenue growth of -39.6% represent sustained multi-year contraction in both top-line and bottom-line, not an isolated single-year event.
- highStock is 58.1% below its 52-week high and 43.9% lower over the past 12 months; current price of ₹430.4 remains 21.4% below the 200-DMA of ₹547.5, indicating a persistent downtrend context.
- mediumDebt-to-equity of 1.643 with a rising debt trend and a quality score of 27 out of 100 — ranked 4th of 6 in the Pharma peer set (peers range 17–54), reflecting below-median balance sheet quality.
- lowOnly 2 news items available in the analysis window, below the threshold for reliable sentiment inference; news coverage is sparse and may not capture recent material developments.
Cross-section contradictions
- 5-year earnings contracted 59.4% yet trailing profit margin stands at 27.88% — the decline appears volume/pricing-driven rather than operational margin collapse, as per-rupee profitability has held while the absolute earnings base eroded.
- Stock is 58.1% below its 52-week high and has lost 43.9% over 12 months, yet trades at a PE of 25.5 — the price correction has not compressed valuation to the lower end of the sector peer range (Dr Reddy 26.5x, Cipla 29.8x).
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days